论文部分内容阅读
目的:观察中药联合微创超低温冷冻消融术治疗肉瘤无法再次手术患者的临床疗效。方法:选取44例不能再次手术的肉瘤患者,随机分为两组,对照组18例予以中药基础治疗,观察组26例予以中药+微创超低温冷冻消融术治疗,4周后评价近期疗效、观察无进展生存期和总生存时间,记录不良反应。结果:观察组疾病控制率明显优于对照组,差异有统计学意义(P<0.05);观察组中位无进展生存期为2个月,对照组为0个月;观察组中位总生存时间为8个月,对照组为5个月,两组生存率比较,差异无统计学意义(P>0.05)。两组不良反应皆为轻度,经观察或对症处理均得到缓解。结论:微创超低温冷冻消融治疗不能再次手术的肉瘤,可提高患者的疾病控制率,延长无进展生存期及总生存期,患者耐受性良好。
Objective: To observe the clinical efficacy of traditional Chinese medicine combined with minimally invasive cryoablation in the treatment of patients with sarcoma can not be reoperation. Methods: Forty-four patients with unresectable sarcoma were randomly divided into two groups. The control group received 18 cases of traditional Chinese medicine. The observation group received 26 cases of traditional Chinese medicine + minimally invasive ultra-low temperature cryoablation. After 4 weeks, the curative effect was observed. Progression-free survival and overall survival time, record adverse reactions. Results: The disease control rate in the observation group was significantly better than that in the control group (P <0.05). The median progression-free survival time was 2 months in the observation group and 0 months in the control group. The median overall survival rate The time was 8 months and the control group was 5 months. There was no significant difference in survival rate between the two groups (P> 0.05). Adverse reactions were mild in both groups, were observed or symptomatic treatment were eased. Conclusion: Minimally invasive cryogenic ablation of sarcomas that can not be operated on again can improve disease control rate, prolong progression-free survival and overall survival, and patients are well tolerated.